CN112930355A - 嵌合分子 - Google Patents
嵌合分子 Download PDFInfo
- Publication number
- CN112930355A CN112930355A CN201980068875.6A CN201980068875A CN112930355A CN 112930355 A CN112930355 A CN 112930355A CN 201980068875 A CN201980068875 A CN 201980068875A CN 112930355 A CN112930355 A CN 112930355A
- Authority
- CN
- China
- Prior art keywords
- cell
- peptide
- cells
- receptor
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18201560 | 2018-10-19 | ||
| EP18201560.2 | 2018-10-19 | ||
| PCT/EP2019/078449 WO2020079264A1 (en) | 2018-10-19 | 2019-10-18 | Chimeric molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112930355A true CN112930355A (zh) | 2021-06-08 |
Family
ID=63965155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980068875.6A Pending CN112930355A (zh) | 2018-10-19 | 2019-10-18 | 嵌合分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210324037A1 (https=) |
| EP (1) | EP3867268A1 (https=) |
| JP (1) | JP2022505107A (https=) |
| KR (1) | KR20210081345A (https=) |
| CN (1) | CN112930355A (https=) |
| AU (1) | AU2019362400A1 (https=) |
| BR (1) | BR112021007418A2 (https=) |
| CA (1) | CA3115007A1 (https=) |
| EA (1) | EA202191083A1 (https=) |
| IL (1) | IL282230A (https=) |
| MX (1) | MX2021004355A (https=) |
| WO (1) | WO2020079264A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109321569A (zh) * | 2018-10-29 | 2019-02-12 | 凯杰(苏州)转化医学研究有限公司 | 一种引物探针组合物及其应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4638712A2 (en) * | 2022-12-22 | 2025-10-29 | Bluesphere Bio, Inc. | Methods for identifying t cell receptors (tcrs) that bind antigens |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999058977A1 (en) * | 1998-05-11 | 1999-11-18 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
| CN105504018A (zh) * | 2016-01-13 | 2016-04-20 | 郑州大学 | Lag-3亲和肽n13、制备方法及其应用 |
| CA2971408A1 (en) * | 2014-12-17 | 2016-06-23 | Sri International | Targeted stealth liposomes loaded with an immunogenic human leukocyte antigen class i restricted peptide |
| US20160177284A1 (en) * | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
| WO2016097334A1 (en) * | 2014-12-19 | 2016-06-23 | ETH Zürich | Chimeric antigen receptors and methods of use |
| CN107286246A (zh) * | 2016-12-28 | 2017-10-24 | 时力生物科技(北京)有限公司 | 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3009756T3 (en) * | 2013-08-05 | 2025-03-31 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors, such as lung cancer including nsclc |
-
2019
- 2019-10-18 CA CA3115007A patent/CA3115007A1/en active Pending
- 2019-10-18 CN CN201980068875.6A patent/CN112930355A/zh active Pending
- 2019-10-18 BR BR112021007418-0A patent/BR112021007418A2/pt not_active Application Discontinuation
- 2019-10-18 KR KR1020217011241A patent/KR20210081345A/ko not_active Withdrawn
- 2019-10-18 MX MX2021004355A patent/MX2021004355A/es unknown
- 2019-10-18 JP JP2021521016A patent/JP2022505107A/ja active Pending
- 2019-10-18 WO PCT/EP2019/078449 patent/WO2020079264A1/en not_active Ceased
- 2019-10-18 AU AU2019362400A patent/AU2019362400A1/en not_active Abandoned
- 2019-10-18 EA EA202191083A patent/EA202191083A1/ru unknown
- 2019-10-18 EP EP19786822.7A patent/EP3867268A1/en not_active Withdrawn
- 2019-10-18 US US17/285,338 patent/US20210324037A1/en not_active Abandoned
-
2021
- 2021-04-11 IL IL282230A patent/IL282230A/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999058977A1 (en) * | 1998-05-11 | 1999-11-18 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
| US20160177284A1 (en) * | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
| CA2971408A1 (en) * | 2014-12-17 | 2016-06-23 | Sri International | Targeted stealth liposomes loaded with an immunogenic human leukocyte antigen class i restricted peptide |
| WO2016097334A1 (en) * | 2014-12-19 | 2016-06-23 | ETH Zürich | Chimeric antigen receptors and methods of use |
| CN105504018A (zh) * | 2016-01-13 | 2016-04-20 | 郑州大学 | Lag-3亲和肽n13、制备方法及其应用 |
| CN107286246A (zh) * | 2016-12-28 | 2017-10-24 | 时力生物科技(北京)有限公司 | 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| GIANLUCA PETRIS: "CD4 and BST-2/tetherin proteins retro-translocate from endoplasmic reticulum to cytosol as partially folded and multimeric molecules", JOURNAL OF BIOLOGICAL MULTIMERIC, pages 1 - 12 * |
| 刘发全: "T细胞介导的肿瘤免疫治疗研究进展", 现代诊断与治疗, no. 05 * |
| 耿磊;: "CD4~+CD25~+T细胞与移植免疫耐受", 国际免疫学杂志, no. 06 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109321569A (zh) * | 2018-10-29 | 2019-02-12 | 凯杰(苏州)转化医学研究有限公司 | 一种引物探针组合物及其应用 |
| CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021004355A (es) | 2021-05-31 |
| IL282230A (en) | 2021-05-31 |
| WO2020079264A1 (en) | 2020-04-23 |
| AU2019362400A1 (en) | 2021-04-22 |
| EP3867268A1 (en) | 2021-08-25 |
| US20210324037A1 (en) | 2021-10-21 |
| JP2022505107A (ja) | 2022-01-14 |
| EA202191083A1 (ru) | 2021-07-23 |
| BR112021007418A2 (pt) | 2021-08-10 |
| CA3115007A1 (en) | 2020-04-23 |
| KR20210081345A (ko) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Parkhurst et al. | Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers | |
| US20240052010A1 (en) | Methods of obtaining tumor-specific t cell receptors | |
| JP7668226B2 (ja) | T細胞組成物を調製するための組成物および方法、ならびにそれらの使用 | |
| Probst et al. | Sarcoma eradication by doxorubicin and targeted TNF relies upon CD8+ T-cell recognition of a retroviral antigen | |
| JP2023025141A (ja) | 野生型抗原及び強力なペプチドミモトープを認識する、患者腫瘍から単離されたt細胞受容体に対する抗原の発見 | |
| Grace et al. | Identification of highly cross-reactive mimotopes for a public T cell response in murine melanoma | |
| AU2025271089A1 (en) | Mammalian mhc peptide display as an epitope selection tool for vaccine design | |
| CN118515748A (zh) | 靶向kras g12突变的抗原结合蛋白及其用途 | |
| CN112930355A (zh) | 嵌合分子 | |
| CN118344477A (zh) | 抗原结合蛋白及其应用 | |
| McAuliffe et al. | Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice | |
| HK40047599A (en) | Mammalian mhc peptide display as an epitope selection tool for vaccine design | |
| HK40047599B (en) | Mammalian mhc peptide display as an epitope selection tool for vaccine design | |
| Zhang | High-throughput identification and analysis of antigen-specific CD4+ T cells | |
| Lund-Johansen et al. | A systematic safety pipeline for selection of T-cell receptors to enter clinical use | |
| Hampton | Identification and Characterization of Tumor Antigens Associated with Breast Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210608 |
|
| WD01 | Invention patent application deemed withdrawn after publication |